
The Scientist Who Said Yes to Everything — and Ended Up in VC
Nandita Shangari didn’t plan to end up in venture capital. She was a toxicologist at Novartis, and said yes to one unplanned opportunity after another, until she’d worked on Kymriah (the first FDA-approved CAR T therapy), ran the Novartis Venture Fund, and ultimately landed at RA Capital Management, where she’s now Managing Director. In this episode, Jen and Mike trace that path with her and get into what she’s learned along the way about the “performance equity” that opens doors, how RA’s incubator builds companies fast, and the real story behind Capstan Therapeutics’ pivot from oncology to autoimmune disease. They also ask her what separates scientists who thrive in venture from the ones who struggle. Find it wherever you listen to podcasts.


